Answers are grounded in this paper and cite their sources.
Once-daily relugolix combination therapy resulted in a significant reduction in menstrual bleeding, as compared with placebo, and preserved bone mineral density in women with uterine fibroids. (Funded by Myovant Sciences; LIBERTY 1 [L1] and LIBERTY 2 [L2] ClinicalTrials.gov numbers, NCT03049735 and NCT03103087, respectively.).
No takes yet. Share an insight, caveat, or question.
Al‐Hendy et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: